FrancophonIA/ELRC3.0 huggingface dataset:
English: Retacrit can be injected under the skin by the patient or their carer if they have been trained appropriately.
Slovenian: Zdravilo Retacrit si lahko pod kožo vbrizga bolnik sam ali mu ga injicira negovalec, če sta bila za to ustrezno usposobljena.
English: Therefore, the CHMP's view was that, as for Eprex/Erypo, the benefit outweighs the identified risks.
Slovenian: Zato je menil, da njegove koristi, tako kot pri zdravilu Eprex/Erypo, odtehtajo znana tveganja.
English: • to reduce the need for blood transfusions in patients with moderate anaemia about to undergo major bone surgery (such as a hip or knee replacement).
Slovenian: • za zmanjšanje potrebe po transfuziji krvi pri bolnikih z zmerno slabokrvnostjo, ki so tik pred velikim operativnim posegom na kosteh (kot je vstavljanje kolka ali kolena).
English: Retacrit was as effective as Eprex/Erypo in correcting and maintaining red blood cell counts.
Slovenian: Zdravilo Retacrit je bilo enako učinkovito kot zdravilo Eprex/Erypo pri izboljševanju in ohranjanju ravni rdečih krvnih celic.
English: Erythropoietin is also used before surgery to increase the number of red blood cells to help patients produce more blood for self-donation.
Slovenian: Eritropoetin se uporablja tudi pred kirurškim posegom, da zviša ravni rdečih krvnih celic in tako pripomore k tvorbi večje količine lastne krvi, ki jo bolnik nato prejme med posegom.
English: All of the patients in the second study had been receiving treatment with Eprex/Erypo for at least three months before they were either switched to Retacrit or remained on Eprex/Erypo for 12 weeks.
Slovenian: V drugi študiji so vse bolnike najmanj tri mesece zdravili z zdravilom Eprex/Erypo, nato pa so za 12 tednov bodisi zamenjali zdravilo z zdravilom Retacrit bodisi še naprej uporabljali zdravilo Eprex/Erypo.
English: Retacrit can also lead to skin rash and influenza (flu)-like symptoms.
Slovenian: Zdravilo Retacrit lahko povzroči tudi kožne izpuščaje in gripi podobne simptome.
English: Retacrit was also as effective as the reference medicine in patients with kidney problems.
Slovenian: Zdravilo Retacrit je bilo pri bolnikih z ledvičnimi težavami enako učinkovito kot referenčno zdravilo.
English: For patients receiving chemotherapy, it must be injected under the skin, and for patients about to undergo surgery, it must be injected into a vein.
Slovenian: Pri bolnikih, ki prejemajo kemoterapijo, je treba zdravilo injicirati pod kožo, pri bolnikih pred kirurškim posegom pa v veno.
English: A hormone called erythropoietin stimulates the production of red blood cells from the bone marrow.
Slovenian: Hormon eritropoetin spodbuja nastajanje rdečih krvnih celic v kostnem mozgu.
English: Retacrit was also effective when it was injected under the skin.
Slovenian: Zdravilo Retacrit je bilo učinkovito tudi ob podkožnem injiciranju.
English: How has Retacrit been studied?
Slovenian: Kako je bilo zdravilo Retacrit raziskano?
English: For patients with kidney problems, Retacrit can be injected into a vein or under the skin.
Slovenian: Zdravilo Retacrit je treba pri bolnikih z ledvičnimi težavami injicirati v veno ali pod kožo.
English: The second study compared the effects of Retacrit with those of Eprex/Erypo in maintaining red blood cell counts in 313 patients.
Slovenian: V drugi študiji so pri 313 bolnikih primerjali učinke zdravila Retacrit z učinki zdravila Eprex/Erypo pri ohranjanju ravni rdečih krvnih celic.
English: Retacrit was studied to show that it is comparable with the reference medicine, Eprex/Erypo, in experimental models and in humans.
Slovenian: Za zdravilo Retacrit so s pomočjo poskusnih modelov in pri ljudeh dokazovali, da je primerljivo z referenčnim zdravilom Eprex/Erypo.
English: What is Retacrit used for?
Slovenian: Za kaj se zdravilo Retacrit uporablja?
English: How is Retacrit used?
Slovenian: Kako se zdravilo Retacrit uporablja?
English: The first study compared the effects of Retacrit with those of Eprex/Erypo in correcting red blood cell counts in 609 patients over 24 weeks.
Slovenian: V prvi študiji so pri 609 bolnikih 24 tednov primerjali učinke zdravila Retacrit z učinki zdravila Eprex/Erypo pri izboljševanju ravni rdečih krvnih celic.
English: What is Retacrit?
Slovenian: Kaj je zdravilo Retacrit?
English: How does Retacrit work?
Slovenian: Kako zdravilo Retacrit deluje?
English: For full details, see the package leaflet.
Slovenian: Za dodatne informacije glejte navodilo za uporabo.
English: The Reference Member State was Germany and the Concerned Member States were Finland and the United Kingdom.
Slovenian: Referenčna država članica je bila Nemčija, zadevni državi članici pa sta bili Finska in Združeno kraljestvo.
English: London, 21 August 2006 EMEA/CHMP/212746/2006
Slovenian: London, 21. avgust 2006 EMEA/CHMP/212746/2006
English: A positive opinion was adopted by majority on 1 June 2006.
Slovenian: Pozitivno mnenje je bilo sprejeto z večino glasov dne 1. junija 2006.
English: The Rapporteur was Dr. Broich and Co-Rapporteurs were Dr. Hudson and Dr. Kuitunen.
Slovenian: Poročevalec je bil dr. Boich, soporočevalca pa sta bila dr. Hudson in dr. Kuitunen.
English: The arbitration procedure started on 15 September 2005 with the adoption of a list of questions.
Slovenian: Arbitražni postopek se je začel 15. septembra 2005 s sprejetjem seznama vprašanj.
English: The Mutual Recognition Procedure started on 24 March 2005.
Slovenian: Postopek za medsebojno priznavanje se je začel 24. marca 2005.
English: The United Kingdom referred the reasons for disagreement to the EMEA on 16 August 2005.
Slovenian: Združeno kraljestvo je agenciji EMEA posredovalo razloge za nesoglasje dne 16. avgusta 2005.
English: This refers to the dosing recommendation for the newborn and this was considered to be of serious public health concern.
Slovenian: Te se nanašajo na priporočila glede odmerjanja za novorojence, kar predstavlja resne pomisleke v zvezi z javnim zdravjem.
English: The Marketing Authorisation Holder provided written explanations on 28 November 2005.
Slovenian: Imetnik dovoljenja za promet z zdravilom je pisna pojasnila predložil dne 28. novembra 2005.
English: The posology in neonates where higher doses were proposed for neonates aged 15-27 days (80 mg/kg) while the standard dose is 20-50mg/kg in the UK for neonates 0-28 days.
Slovenian: V zvezi z odmerjanjem pri novorojencih so bili predlagani višji odmerki za novorojence, stare od 15 do 27 dni (80 mg/kg), medtem ko je v Združenem kraljestvu standardni odmerek 20-50 mg/kg za novorojence, stare od 0 do 28 dni.
English: Significant difference has been identified with regard to the proposed SPC compared to the SPC of the reference product in the UK.
Slovenian: V zvezi s predlaganim Povzetkom glavnih značilnosti zdravila (SPC) so bile ugotovljene pomembne razlike v primerjavi s SPC referenčnega izdelka v Združenem kraljestvu.
English: During their May 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Ceftriaxone Tyrol Pharma and associated names, that the objections raised by United Kingdom should
Slovenian: Med svojim zasedanjem maja 2006 je CHMP na podlagi vseh posredovanih podatkov in znanstvene razprave v okviru Odbora, sprejel mnenje, da je razmerje med tveganji in koristmi za zdravilo Ceftriaxone Tyrol Pharma in povezana imena ugodno, da ugovori, podani s strani Združenega
English: Depending on the mode of surgery and the expected spectrum of pathogens ceftriaxone should be combined with an appropriate antimicrobial agent with additional anaerobic coverage.
Slovenian: Odvisno od vrste kirurškega posega in pričakovanega spektra patogenih mikroorganizmov je treba ceftriakson dajati skupaj z ustreznim protimikrobnim sredstvom, ki dodatno deluje na druge anaerobe.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Ceftriaxone Tyrol Pharma and associated names International Non-Proprietary Name (INN): Ceftriaxone
Slovenian: ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 29(2)1 ZA Ceftriaxone Tyrol Pharma in povezana imena Mednarodno nelastniško ime (INN): Ceftriakson
English: It is indicated for the treatment of the following infections when caused by micro-organisms that are susceptible to ceftriaxone and if parenteral treatment is necessary:
Slovenian: Indiciran je za zdravljenje spodaj navedenih okužb, kadar jih povzročijo na ceftriakson občutljivi organizmi in če je potrebno parenteralno zdravljenje:
English: not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Slovenian: kraljestva, ne bi smeli preprečiti podelitve dovoljenja za promet z zdravilom, ter da je treba Povzetek glavnih značilnosti zdravila, označevanje in Navodila za uporabo referenčne države članice dopolniti.
English: Ceftriaxone Tyrol Pharma and associated names, 1g and 2 g powder for solution for injection/infusion, is an antibiotic, being a third generation cephalosporin.
Slovenian: Ceftriaxone Tyrol Pharma in povezana imena, 1g in 2 g prašek za raztopino za injiciranje/infundiranje je antibiotik, cefalosporin tretje generacije.
English: Ceftriaxone is indicated for perioperative prophylaxis in patients with a certain risk of severe postoperative infections.
Slovenian: • pljučnica Ceftriakson se uporablja za preprečevanje okužb pri kirurških posegih pri bolnikih, pri katerih obstaja določeno tveganje, da pride do hudih okužb po operaciji.
English: Sandoz GmbH submitted applications for mutual recognition of Ceftriaxone Tyrol Pharma and associated names, 1g and 2g, solution for injection/infusion on the basis of the marketing authorisation granted by Germany on 13 August 2002.
Slovenian: Družba Sandoz GmbH je predložila vloge za medsebojno priznavanje zdravila Ceftriaxone Tyrol Pharma in povezana imena, 1 g in 2 g prašek za raztopino za injiciranje/infundiranje, na osnovi dovoljenja za promet z zdravilom, ki ga je izdala Nemčija dne 13. avgusta 2002.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rixubis on 19 December 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Rixubis, veljavno po vsej Evropski uniji, izdala 19 decembra 2014.
English: It can be used in patients of all ages, and for short-term or long-term use.
Slovenian: Uporablja se lahko pri bolnikih vseh starosti ter je primerno za kratkotrajno ali dolgotrajno uporabo.
English: Rixubis nonacog gamma
Slovenian: Rixubis nonakog gama
English: What measures are being taken to ensure the safe and effective use of Rixubis?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rixubis?
English: Other information about Rixubis
Slovenian: Druge informacije o zdravilu Rixubis
English: The safety profile was considered acceptable and was outweighed by the beneficial effects.
Slovenian: Varnostni profil je bil ocenjen kot sprejemljiv glede na koristi.
English: The full EPAR and risk management plan summary for Rixubis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Rixubis sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Rixubis.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rixubis.
English: The effect of treatment in stopping bleeding episodes was rated excellent in 41% of cases and good in a further 55%.
Slovenian: Učinek zdravila pri zaustavljanju epizode krvavitve je bil ocenjen kot odličen v 41 % primerov in kot dober v naslednjih 55 %.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Rixubis's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Rixubis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: It is not intended to provide practical advice on how to use Rixubis.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: In the first study, involving 73 patients aged 12 to 59 years, 249 bleeding episodes were treated with Rixubis.
Slovenian: V prvi študiji, v kateri je sodelovalo 73 bolnikov, starih od 12 do 59 let, so z zdravilom Rixubis zdravili 249 epizod krvavitev.
English: A risk management plan has been developed to ensure that Rixubis is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Rixubis je bil pripravljen načrt obvladovanja tveganj.
English: The evaluation of these studies also indicated that Rixubis was distributed in the body similarly to another approved factor IX product.
Slovenian: Vrednotenje teh študij je tudi nakazalo, da se je zdravilo Rixubis po telesu razporedilo podobno kot drugo odobreno zdravilo s faktorjem IX.
English: For further information, see the summary of product characteristics (also part of the EPAR).
Slovenian: Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako sestavni del EPAR).
English: Hypersensitivity (allergic) reactions may occur rarely, and can include angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, hypotension (low blood pressure), feeling tired or restless, nausea (feeling sick) or vomiting, tachycardia (rapid heartbeat), tightness of the chest, wheezing and tingling sensations.
Slovenian: Redko se lahko pojavijo preobčutljivostne (alergijske) reakcije, ki lahko vključuje angioedem (otekanje podkožnih tkiv), pekoč občutek in zbadanje na mestu injiciranja, mrzlico, pordelost, srbeč izpuščaj, glavobol, koprivnico, hipotenzijo (nizek krvni tlak), utrujenost ali nemirnost, navzejo (slabost) ali bruhanje, tahikardijo (hitro bitje srca), tiščanje v prsih, težko dihanje in ščemenje.
English: A second study involved 23 children aged from just under 2 to nearly 12 years of age, who experienced 26 bleeding episodes during the study: treatment of bleeding episodes was rated as excellent in 50% of cases and good in another 46%, and the average bleeding rate was reduced from 6.8 to 2.7 bleeds per year.
Slovenian: V drugi študiji je sodelovalo 23 otrok, starih od skoraj 2 do skoraj 12 let, pri katerih je med študijo prišlo do 26 epizod krvavitev: zdravljenje epizod krvavitev je bilo ocenjeno kot odlično v 50 % primerov in kot dobro v nadaljnjih 46 %, povprečno število krvavitev pa se je zmanjšalo s 6,8 na 2,7 krvavitve na leto.
English: This lack causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Slovenian: To povzroča zaplete pri strjevanju krvi, kot je krvavenje v sklepe, mišice ali notranje organe.
English: The most common side effects with Rixubis (which may affect up to 1 in 10 people) are dysgeusia (taste disturbances) and pain in the limbs.
Slovenian: Najpogostejši neželeni učinki zdravila Rixubis (ki lahko prizadenejo največ 1 osebo od 10) so disgevzija (motnje okušanja) in bolečine v okončinah.
English: With respect to prevention of bleeding, the average bleeding rate during treatment was 4.26 bleeds a year, compared with an average of about 17 per year before enrolment.
Slovenian: Kar zadeva preprečevanje krvavitev, je bilo povprečno število krvavitev 4,26 krvavitve na leto v primerjavi s povprečno 17 na leto pred vključitvijo v študijo.
English: In some cases, reactions become severe (anaphylaxis) and may be associated with dangerously steep falls in blood pressure.
Slovenian: V nekaterih primerih reakcije postanejo hude (anafilaksija) ter so lahko povezane z nevarno naglim in velikim zmanjšanjem krvnega tlaka.
English: Effectiveness in stopping bleeding was measured on a standard scale in which ‘excellent' meant complete relief of pain and no signs of bleeding after a single dose of the medicine, and ‘good' meant relief of pain and signs of improvement with a single dose, although further doses might be needed for complete resolution.
Slovenian: Učinkovitost pri zaustavljanju krvavitev so merili s standardno lestvico, pri kateri je „odlično“ pomenilo, da bolnik po enem odmerku zdravila ni več čutil bolečine in ni imel več nobenih znakov krvavitve, „dobro“ pa je pomenilo, da se je pri bolniku po enem odmerku zmanjšala bolečina in so bili vidni znaki izboljšanja, vendar pa bi bili za popolno odpravo simptomov morda potrebni nadaljnji odmerki.
English: The dose and frequency of treatment depend on the patient's bodyweight and whether Rixubis is used to treat or prevent bleeding, as well as the seriousness of the haemophilia, the extent and location of the bleeding and the patient's age and health.
Slovenian: Odmerek in pogostost uporabe zdravila sta odvisna od telesne mase bolnika, tega, ali se zdravilo Rixubis uporablja za zdravljenje ali preprečevanje krvavitev, od resnosti hemofilije, obsega in mesta krvavitve ter bolnikove starosti in zdravja.
English: Nonacog gamma is not extracted from human blood but is made by a method known as ‘recombinant DNA technology': it is made by hamster cells into which a gene (DNA) has been introduced that makes the cells able to produce the human clotting factor.
Slovenian: Nonakog gama se ne pridobiva iz človeške krvi, temveč se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri v hrčkove celice vstavijo gen (DNK), s katerim te lahko tvorijo humani faktor strjevanja krvi.
English: What are the risks associated with Rixubis?
Slovenian: Kakšna tveganja so povezana z zdravilom Rixubis?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rixubis, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Rixubis in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: What is Rixubis and what is it used for?
Slovenian: Kaj je zdravilo Rixubis in za kaj se uporablja?
English: The benefits of Rixubis in treating and preventing bleeding episodes have been shown in three main studies involving patients with severe or moderately severe haemophilia B. None of the studies compared the effectiveness of Rixubis directly with another medicine.
Slovenian: Koristi zdravila Rixubis pri zdravljenju in preprečevanju epizod krvavitev so dokazali v treh glavnih študijah, v katerih so sodelovali bolniki s hudo ali zmerno hudo hemofilijo B. V nobeni od študij niso neposredno primerjali učinkovitosti zdravila Rixubis z drugim zdravilom.
English: Why is Rixubis approved?
Slovenian: Zakaj je bilo zdravilo Rixubis odobreno?
English: What benefits of Rixubis have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Rixubis izkazalo v študijah?
English: Rixubis can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia.
Slovenian: Izdaja zdravila Rixubis je le na recept, zdravljenje pa mora biti uvedeno pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hemofilije.
English: The Committee considered that Rixubis had been shown to be effective in preventing and treating bleeding episodes in adults and children with haemophilia B, and was also effective in allowing them to undergo surgery safely.
Slovenian: Odbor je menil, da je bilo dokazano, da je zdravilo Rixubis učinkovito pri preprečevanju in zdravljenju epizod krvavitev pri odraslih in otrocih s hemofilijo B, poleg tega pa jim je omogočilo varen kirurški poseg.
English: For more information about treatment with Rixubis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Rixubis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: For full details, see the package leaflet.
Slovenian: Za vse podrobnosti glejte navodilo za uporabo.
English: Patients or their carers may be able to administer Rixubis themselves at home once they have been trained appropriately.
Slovenian: Bolniki si lahko doma sami injicirajo zdravilo Rixubis oziroma to storijo njihovi negovalci, ko se za to ustrezno usposobijo.
English: Rixubis must not be used in patients who are hypersensitive (allergic) to nonacog gamma or any of its other ingredients, or who are known to be allergic to hamster protein.
Slovenian: Zdravila Rixubis ne smejo uporabljati bolniki, ki so preobčutljivi za (alergični na) nonakog gama ali katero koli drugo sestavino zdravila ali na beljakovine hrčkov.
English: Rixubis is available as a powder and solvent that are mixed together to make a solution for injection into a vein.
Slovenian: Zdravilo Rixubis je na voljo v obliki praška in vehikla, ki se zmešata v raztopino za injiciranje v veno.
English: For practical information about using Rixubis, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Rixubis naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: The active substance in Rixubis, nonacog gamma, is a version of human factor IX and helps the blood to clot in the same way.
Slovenian: Zdravilna učinkovina zdravila Rixubis, nonakog gama, je različica humanega faktorja IX in na enak način pomaga pri strjevanju krvi.
English: Patients with haemophilia B lack factor IX, which is needed for blood to clot properly.
Slovenian: Bolnikom s hemofilijo B primanjkuje faktorja IX, ki je potreben za pravilno strjevanje krvi.
English: For the full list of all side effects with Rixubis see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rixubis, glejte navodilo za uporabo.
English: Rixubis can therefore be used to replace the missing factor IX, giving temporary control of the bleeding disorder.
Slovenian: Zdravilo Rixubis se tako uporablja za nadomeščanje manjkajočega faktorja IX, s čimer se začasno vzpostavi nadzor nad motnjo strjevanja krvi.
English: Rixubis is a medicine used to treat and prevent bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of factor IX.
Slovenian: Zdravilo Rixubis se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo B, prirojeno motnjo strjevanja krvi zaradi pomanjkanja faktorja IX.
English: How does Rixubis work?
Slovenian: Kako zdravilo Rixubis deluje?
English: Rixubis contains the active substance nonacog gamma.
Slovenian: Zdravilo Rixubis vsebuje zdravilno učinkovino nonakog gama.
English: How is Rixubis used?
Slovenian: Kako se zdravilo Rixubis uporablja?
English: In a third study, Rixubis was given to 14 patients undergoing surgery; treatment with Rixubis kept blood loss during the surgery to levels expected in patients without haemophilia B.
Slovenian: V tretji študiji je zdravilo Rixubis prejelo 14 bolnikov, ki so čakali na kirurški poseg.
English: PRAC also considered grounds submitted by LFB Biomedicaments as basis for their request for re-examination of the PRAC recommendation and the views of two experts meetings held on 22 February and 3 August 2017.
Slovenian: Odbor PRAC je upošteval tudi razloge, ki jih je predložila družba LFB Biomedicaments kot podlago za zahtevo za ponovno preučitev priporočila odbora PRAC, ter mnenji z dveh strokovnih sestankov, ki sta potekala 22. februarja in 3. avgusta 2017;
English: Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Slovenian: HAemophilia Safety Surveillance (EUHASS) project.